AU676491B2 - Immunopotentiatory agents - Google Patents

Immunopotentiatory agents Download PDF

Info

Publication number
AU676491B2
AU676491B2 AU48311/93A AU4831193A AU676491B2 AU 676491 B2 AU676491 B2 AU 676491B2 AU 48311/93 A AU48311/93 A AU 48311/93A AU 4831193 A AU4831193 A AU 4831193A AU 676491 B2 AU676491 B2 AU 676491B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
virus
cancer
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU48311/93A
Other languages
English (en)
Other versions
AU4831193A (en
Inventor
John Richard Rhodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220715A external-priority patent/GB9220715D0/en
Priority claimed from GB929226874A external-priority patent/GB9226874D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU4831193A publication Critical patent/AU4831193A/en
Application granted granted Critical
Publication of AU676491B2 publication Critical patent/AU676491B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Securing Globes, Refractors, Reflectors Or The Like (AREA)
  • Planar Illumination Modules (AREA)
  • Illuminated Signs And Luminous Advertising (AREA)
AU48311/93A 1992-10-01 1993-09-30 Immunopotentiatory agents Ceased AU676491B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB929220715A GB9220715D0 (en) 1992-10-01 1992-10-01 Immunopotentiatory agent and physiologically acceptable salts thereof
GB9220715 1992-10-01
GB929226874A GB9226874D0 (en) 1992-12-23 1992-12-23 Immunopotentiatory agents and physiologically acceptable salts thereof
GB9226874 1992-12-23
PCT/GB1993/002039 WO1994007479A2 (en) 1992-10-01 1993-09-30 Immunopotentiatory agents

Publications (2)

Publication Number Publication Date
AU4831193A AU4831193A (en) 1994-04-26
AU676491B2 true AU676491B2 (en) 1997-03-13

Family

ID=26301715

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48311/93A Ceased AU676491B2 (en) 1992-10-01 1993-09-30 Immunopotentiatory agents

Country Status (24)

Country Link
US (1) US5508310A (enExample)
EP (3) EP0678298A3 (enExample)
JP (2) JPH07504204A (enExample)
KR (1) KR100348775B1 (enExample)
CN (1) CN1213746C (enExample)
AT (1) ATE146075T1 (enExample)
AU (1) AU676491B2 (enExample)
CA (1) CA2124677C (enExample)
CZ (1) CZ132794A3 (enExample)
DE (1) DE69306545T2 (enExample)
DK (1) DK0609606T3 (enExample)
ES (1) ES2096215T3 (enExample)
GR (1) GR3022541T3 (enExample)
HR (1) HRP931243A2 (enExample)
HU (1) HUT70482A (enExample)
IL (1) IL107157A0 (enExample)
MX (1) MX9306079A (enExample)
NZ (1) NZ256110A (enExample)
RU (1) RU94028670A (enExample)
SG (1) SG48993A1 (enExample)
SI (1) SI9300514A (enExample)
SK (1) SK65294A3 (enExample)
WO (1) WO1994007479A2 (enExample)
YU (1) YU62793A (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3539795A (en) * 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
WO1998052573A1 (en) * 1997-05-20 1998-11-26 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
KR100680014B1 (ko) * 1997-10-03 2007-02-09 갈레니카 파마슈티칼스 인크. 이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
WO2001046125A2 (en) * 1999-12-21 2001-06-28 Astrazeneca Ab Cd45 inhibitors
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
EP1265840A2 (en) * 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
AU2001251491A1 (en) * 2000-04-11 2001-10-23 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
PL367102A1 (en) * 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
AU2004241107A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
SG10202009963PA (en) 2011-01-07 2020-11-27 Allergan Inc Melanin modification compositions and methods of use
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) * 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173262A2 (de) * 1984-08-24 1986-03-05 Carnivora-Deutschland GmbH Verwendung von 1,4-Naphthochinon-Derivaten in niedrigen Konzentrationen zur Immunstimulation
EP0217041A1 (de) * 1985-08-09 1987-04-08 Schleicher, Peter, Dr. med. Mundpflegemittel
EP0499015A1 (en) * 1991-02-15 1992-08-19 Fockerman, Jasmine Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54126731A (en) * 1978-03-20 1979-10-02 Rikagaku Kenkyusho Carcinostatic agent
JPS5545658A (en) * 1978-09-28 1980-03-31 Rikagaku Kenkyusho Carcinostatic agent
JPS5569510A (en) * 1978-11-16 1980-05-26 Mitsubishi Chem Ind Ltd Carcinostatic agent
GR76950B (enExample) * 1980-12-18 1984-09-04 Wellcome Found
LU85365A1 (de) * 1984-05-16 1986-01-29 Chimicasa Gmbh Verfahren und praeparat zur stimulierung des immunsystems
JPS63264409A (ja) * 1988-01-13 1988-11-01 Rikagaku Kenkyusho 制癌剤
JPH03254007A (ja) * 1990-03-01 1991-11-13 Tir Syst Ltd 非吸収性で且つ透過率が可変のカバーを有した照明装置
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173262A2 (de) * 1984-08-24 1986-03-05 Carnivora-Deutschland GmbH Verwendung von 1,4-Naphthochinon-Derivaten in niedrigen Konzentrationen zur Immunstimulation
EP0217041A1 (de) * 1985-08-09 1987-04-08 Schleicher, Peter, Dr. med. Mundpflegemittel
EP0499015A1 (en) * 1991-02-15 1992-08-19 Fockerman, Jasmine Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents

Also Published As

Publication number Publication date
RU94028670A (ru) 1996-05-20
CA2124677A1 (en) 1994-04-14
NZ256110A (en) 1997-07-27
CA2124677C (en) 2008-09-09
EP0678298A3 (en) 1996-05-29
WO1994007479A2 (en) 1994-04-14
ES2096215T3 (es) 1997-03-01
US5508310A (en) 1996-04-16
KR100348775B1 (ko) 2003-02-11
HRP931243A2 (en) 1995-12-31
GR3022541T3 (en) 1997-05-31
MX9306079A (es) 1994-06-30
HU9401631D0 (en) 1994-08-29
CZ132794A3 (en) 1995-02-15
ATE146075T1 (de) 1996-12-15
EP0609606B1 (en) 1996-12-11
YU62793A (sh) 1998-05-15
EP0614357A1 (en) 1994-09-14
JPH072660A (ja) 1995-01-06
CN1213746C (zh) 2005-08-10
HUT70482A (en) 1995-10-30
EP0609606A1 (en) 1994-08-10
JP3717950B2 (ja) 2005-11-16
AU4831193A (en) 1994-04-26
JPH07504204A (ja) 1995-05-11
CN1091005A (zh) 1994-08-24
DE69306545T2 (de) 1997-04-03
IL107157A0 (en) 1993-12-28
SG48993A1 (en) 1998-05-18
WO1994007479A3 (en) 1994-07-21
DE69306545D1 (de) 1997-01-23
DK0609606T3 (enExample) 1997-03-17
SK65294A3 (en) 1995-03-08
SI9300514A (en) 1994-06-30
EP0678298A2 (en) 1995-10-25

Similar Documents

Publication Publication Date Title
CA2124677C (en) Immunopotentiatory agents and physiologically acceptable salts thereof
US6197743B1 (en) Compositions and methods for the treatment of viral disorders
Alwan et al. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells
EP0969869A2 (en) Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
US20040228907A1 (en) Methods and pharmaceutical compositions employing desmethylselegiline
US5872151A (en) Immunopotentiatory agents and physiologically acceptable salts thereof
US5958980A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
AU2017267172A1 (en) A specific trifluoroethyl quinoline analogue for use in the treatment of APDS
CA2109435C (en) Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals
Capron et al. The Second Receptor for IgE in Eosinophil
US6096786A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
EP0914824A1 (en) Preventive and remedy for viral infections
JP2000501085A (ja) 多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用
CN115697301A (zh) 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法
US20090176743A1 (en) Methods for treating or preventing reactivation of a latent herpesvirus infection
JP2009501737A (ja) レイノー現象の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用
White Antiviral chemotherapy, interferons and vaccines
JP2000514066A (ja) 抗ウイルス性抗腫瘍剤としてのインターロイキン―８
EP0082667A1 (en) Pharmaceutical compositions
CA1332222C (en) Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences
JPH07188032A (ja) インフルエンザ治療薬
CN102770132B (zh) 苯甲酸衍生物的药物用途
WO2022076683A1 (en) Methods of treating coronaviral infection with obeticholic acid
JP2000281571A (ja) 免疫賦活剤
JPH04506517A (ja) ３，３―ジ置換インドリンの鼻腔内投与